<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer Treatment Today &#187; GE Junction Cancer</title>
	<atom:link href="http://cancertreatmenttoday.org/category/layperson-articles/gastric-stomach-cancer/ge-junction-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://cancertreatmenttoday.org</link>
	<description>Knowledge is Power</description>
	<lastBuildDate>Thu, 26 Mar 2026 23:39:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Tykerb for stomach cancer</title>
		<link>http://cancertreatmenttoday.org/tykerb-for-stomach-cancer/</link>
		<comments>http://cancertreatmenttoday.org/tykerb-for-stomach-cancer/#comments</comments>
		<pubDate>Fri, 02 Nov 2012 12:24:51 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Gastric (Stomach) Cancer]]></category>
		<category><![CDATA[GE Junction Cancer]]></category>
		<category><![CDATA[Layperson]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?p=9678</guid>
		<description><![CDATA[Stomach cancer is known to have amplification of the ErbB2 (HER2) gene and responds to the drug Herceptin, which used this pathwayto attach cacner cells . Recently, there has been an interest in using Tyker(lapatinib) which is a drug that utalizes the same mechanism of action as Herceptin. One such trial is: LOGiC &#8211; Lapatinib Optimization Study [...]]]></description>
			<content:encoded><![CDATA[<p>Stomach cancer is known to have amplification of the ErbB2 (HER2) gene and responds to the drug Herceptin, which used this pathwayto attach cacner cells . Recently, there has been an interest in using Tyker(lapatinib) which is a drug that utalizes the same mechanism of action as Herceptin. One such trial is: LOGiC &#8211; Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. This is an international multi-center trial for patients stomach, esophagus, or gastro-esophageal junction cancer with amplification of the ErbB2 (HER2) gene. The triallooks at whether lapatinib, when added to the chemotherapy regimen, capecitabine extends the time to progression and overall life. Chemothrapy is administered to all patients, who then randomly get either lapatinib or placebo. There is evidence of effectiveness for braa metastaes, at least in breast cancer(Lin et al).</p>
<p>Iqbal et al showed that Tykerb is an effective first line drug. The evidence thus far suggests that the combination of lapatinib + capecitabine shows promising efficacy and is well tolerated. The same appears to be true of Taxol and lapatinib and studies of this combination are ongoing.</p>
<p>A number of issues remain to study: how to combine Tykerb with toehr drugs, the role of Taykeb in patients previousely treated with Herceptin, and efficacyfor brain metastases.</p>
<p> For Professional version see<span style="color: #ff0000;"><a title="Tykerb goastric cancer – pro" href="http://cancertreatmenttoday.org/tykerb-goastric-cancer-pro/"><span style="color: #ff0000;"> here</span></a></span></p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/tykerb-for-stomach-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Research in GE Junction Gastric Cancer</title>
		<link>http://cancertreatmenttoday.org/research-in-ge-junction-gastric-cancer/</link>
		<comments>http://cancertreatmenttoday.org/research-in-ge-junction-gastric-cancer/#comments</comments>
		<pubDate>Mon, 13 Aug 2012 13:58:09 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Gastric (Stomach) Cancer]]></category>
		<category><![CDATA[GE Junction Cancer]]></category>
		<category><![CDATA[Layperson]]></category>
		<category><![CDATA[Research in Oncology]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?p=4520</guid>
		<description><![CDATA[Gatrointestinal junction(GE) cancer (where esophagus and stomach meet) is a type of cancer that has similarities to both gastric and esophageal cancer. Since GE Junctions cancers that express HER turned out to respond well to Herceptin, there is great interest in targeting other molecules, such as the epidermal growth factor receptor, vascular endothelial growth factor [...]]]></description>
			<content:encoded><![CDATA[<p>Gatrointestinal junction(GE) cancer (where esophagus and stomach meet) is a type of cancer that has similarities to both gastric and esophageal cancer. Since GE Junctions cancers that express HER turned out to respond well to Herceptin, there is great interest in targeting other molecules, such as the epidermal growth factor receptor, vascular endothelial growth factor receptor, and P13k/Akt/mTor pathway, as well as the insulin-like growth factor receptor, c-Met pathways, fibroblast growth factor receptor, and other pathways in this type of cancer. Much remains to be done before clinical therapies based on this concept become available and proven but there is much research activity. One study looking at a C-MET inhibitor is: MET111643 ,A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer.</p>
<p>Read the Professional version <strong><span style="color: #ff0000;"><a title="Research in GE Junction Gastric Cancer – pro" href="http://cancertreatmenttoday.org/research-in-ge-junction-gastric-cancer-pro/"><span style="color: #ff0000;">here</span></a></span></strong>.</p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/research-in-ge-junction-gastric-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
